Durable Complete Response achieved in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL) patient treated with a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy with a PD-1 Knockout: Case Report from the CB-010 ANTLER Trial
AMERICAN JOURNAL OF HEMATOLOGY(2023)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要